KYLEENA (levonorgestrel) by Bayer. Approved for progestin [epc]. First approved in 2016.
Drug data last refreshed 1h ago · AI intelligence enriched 1h ago
KYLEENA is a levonorgestrel-releasing intrauterine system (IUS) approved in 2016 for contraception. It is a small-molecule progestin delivered directly into the uterus over an extended period. The device provides long-acting reversible contraception by releasing the synthetic progestin levonorgestrel locally.
Product approaching loss of exclusivity with modest Part D claims; brand team focus is likely shifting to lifecycle extension or managed decline strategies.
Progestin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function Among Young African Women
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on KYLEENA at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Working on KYLEENA offers exposure to contraceptive marketing, women's health positioning, and device-based product management within a declining franchise. Professionals joining this team should expect focus on market defense, pricing optimization, and transition planning ahead of generic entry rather than growth initiatives.